The New England journal of medicine 2017-11-09
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Abstract
Background
Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma.
Methods
In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-to-treat population.
Results
At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001). Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, respectively. Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment.
Conclusions
Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906 ; Eudra-CT number, 2014-002351-26 .).
Related Questions
In elderly patients with advanced melanoma and idiopathic pulmonary fibrosis receiving active antifibrotic therapy, would neoadjuvant or adjuvant immune checkpoint inhibition be preferred?
Given this scenario, it is most important to have a goal-of-care discussion. That would help sort out the optimal treatment for such patients. Always treat to relieve pain as needed.
How do you approach patients with very low risk stage IIIA cutaneous melanoma for adjuvant immunotherapy?
Although it may seem that Stage 3A is a higher stage than Stage 2B and 2C, it must be kept in mind that according to AJCC 8 criteria, 2B and 2C melanomas are thicker (with to without ulceration), and a 3A melanoma is by definition a thinner melanoma. A thin melanoma (<2mm) is called a 3A melanoma be...
How do you approach patients with stage III melanoma for adjuvant treatment?
Currently, there are FDA-approved adjuvant systemic therapy for stage III melanoma. These were based on the CheckMate 238 study (adjuvant nivolumab), KEYNOTE-054 (adjuvant pembrolizumab), and COMBI-AD study (adjuvant dabrafenib/trametinib). The KEYNOTE-054 compared adjuvant pembro vs placebo, with H...
How do you approach patients with early stage resected melanoma (Stage IIA) for adjuvant treatment?
The current guidelines do not recommend adjuvant treatment for patients with stage I/IIA disease outside the setting of a clinical trial. Major trials including the KEYNOTE-054 and CheckMate 238 have excluded patients with early stage I/IIA disease. However, in patients with stage IIB/IIC disease ad...
Would you offer adjuvant immune checkpoint therapy for a patient with resected mucosal melanoma with a tumor thickness >4.0 mm with negative LN involvement?
Although adjuvant therapy is an option for patients with thick cutaneous melanomas, based on the results of the KEYNOTE-716 clinical trial (as well as CheckMate76K clinical trials), these trials limited accruals to cutaneous melanoma patients only. Thus, the efficacy of adjuvant immune checkpoint th...
Would you give adjuvant nivolumab for IIIA melanoma?
This is a very timely and excellent question. There have been recently three landmark adjuvant studies, and two recent FDA approvals that have changed our approach for patients with resected melanoma. All three studies were based on AJCC staging 7th edition and required patients to undergo complete ...
What treatment would you offer to a patient after resection of a solitary metastatic melanoma from the brain without evidence of other sites of disease?
Resected stage IV melanoma, including patients with resected brain metastases, was included in the CHECKMATE 238 study of adjuvant nivolumab vs. adjuvant ipi published by Weber et al in NEJM 2017, which was a positive study overall with improved RFS in the nivolumab arm. The magnitude of effect in t...
What would you recommend as adjuvant treatment for a patient with Stage III melanoma?
Good question at just the right time. As of last week the treatment of stage III melanoma has dramatically changed based on 2 trials reported in the NEJM. The first trial in 906 patients demonstrating that nivolumab is superior to iplimumab with much less toxicity, was stopped early because of clear...
What systemic therapy, if any, would you recommend for a patient with oligometastatic melanoma who is rendered NED after resection?
This remains a very timely question and currently the data would allow for two options : observation vs adjuvant therapy with nivolumab.Observation is a very reasonable option since we know that this can result in prolonged overall and occasionally relapse-free survival in a subset of patients; howe...